90 related articles for article (PubMed ID: 15011594)
1. [First nucleotide analog with noteworthy safety profile. Tenofovir effective in all stages of the infection].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():62-4. PubMed ID: 15011594
[No Abstract] [Full Text] [Related]
2. [Resistance in a new light. About mutations and their interactions].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():64-5. PubMed ID: 15011595
[No Abstract] [Full Text] [Related]
3. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
4. [Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():62-4. PubMed ID: 12043078
[No Abstract] [Full Text] [Related]
5. [First nucleotide analog on the market. New drug for the pretreated patient].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():84. PubMed ID: 12043094
[No Abstract] [Full Text] [Related]
6. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
Rifkin BS; Perazella MA
Am J Med; 2004 Aug; 117(4):282-4. PubMed ID: 15308442
[No Abstract] [Full Text] [Related]
8. [No comparison with NRTI. Tenofovir is robust against resistance trouble].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079
[No Abstract] [Full Text] [Related]
9. [Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():86-9. PubMed ID: 11373792
[No Abstract] [Full Text] [Related]
10. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
[TBL] [Abstract][Full Text] [Related]
11. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature.
Malik A; Abraham P; Malik N
J Infect; 2005 Aug; 51(2):E61-5. PubMed ID: 16038754
[TBL] [Abstract][Full Text] [Related]
12. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
13. Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Verhelst D; Monge M; Meynard JL; Fouqueray B; Mougenot B; Girard PM; Ronco P; Rossert J
Am J Kidney Dis; 2002 Dec; 40(6):1331-3. PubMed ID: 12460055
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of tenofovir disoproxil fumarate.
Sax PE; Gallant JE; Klotman PE
AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.
TreatmentUpdate; 2002 Aug; 14(6):5. PubMed ID: 12238451
[No Abstract] [Full Text] [Related]
16. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
[No Abstract] [Full Text] [Related]
17. Anti-HIV agents. Tenofovir looks good in initial therapy.
TreatmentUpdate; 2002 Aug; 14(6):3-5. PubMed ID: 12238450
[No Abstract] [Full Text] [Related]
18. Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Breton G; Alexandre M; Duval X; Prie D; Peytavin G; Leport C; Vildei JL
Scand J Infect Dis; 2004; 36(6-7):527-8. PubMed ID: 15307594
[TBL] [Abstract][Full Text] [Related]
19. BMS issues PK notice regarding ATV + TDF.
IAPAC Mon; 2003 Sep; 9(9):203. PubMed ID: 14672069
[No Abstract] [Full Text] [Related]
20. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
